Compare Docusign Inc (DOCU) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Cassava Sciences Inc — how do they compare? Docusign Inc trades at $59.04 (market cap $11.39B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Docusign Inc is far larger — about 238.5× Cassava Sciences Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | FLNA | |
|---|---|---|
Market Cap | $11.39B | $47.75M |
Sector | Technology | Health |
52-Week High | $85.01 | $4.64 |
52-Week Low | $41.75 | $0.87 |
Enterprise Value | $10.76B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $60.26, up 5.91% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support at $58 and resistance at $61. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. Analyst consensus is mixed with a $55.40 price target below the current price, indicating caution despite recent strength.
Outlook balances robust profitability and growth against high valuation and cash flow concerns. The stock offers upside if earnings momentum continues but faces risks from competitive pressures and reliance on subscription renewals. Institutional activity shows mixed signals with some funds reducing stakes.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
